Neuralstem, Inc. (CUR) Offers Better Way to Treat Diseases of the Brain and Central Nervous System

Neuralstem is a Maryland-based company using its patented technology to produce neural stem cells of the human brain and spinal cord, with associated cell treatment therapies in development for ALS (Lou Gehrig’s disease), spinal cord injury, ischemic spastic paraplegia, ischemic stroke, and many other diseases of the brain and nervous system. Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system (CNS) conditions.

Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing CNS in virtually unlimited numbers from a single donated tissue. The company can produce neural stem cells of the human brain and spinal cord in commercial quantities, and control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

There are two primary ways that these cells can provide therapeutic effects: Transplanted cells can help create new circuitry, and transplanted cells can express factors that protect existing cells. The company is confident that Neuralstem’s cells do both. Unlike other stem cell tech¬nologies, Neuralstem is able to grow region-specific cells that are already suited to the task prescribed to them once transplanted into the CNS. For instance, in spinal cord indications the company will be using human spinal cord stem cells only. Once inside the body, Neuralstem cells do not become any cell other than that to which they are fated.

Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA. The company has also submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury. In addition, the company is in an FDA-approved Phase Ib safety trial evaluating NSI-189, the first of its four proprietary, neurogenic small molecule compounds, for the treatment of major depressive disorder (MDD).

Neuralstem recently announced that it has received approval to begin a trial to treat stroke patients in China. The trial will be conducted at the Ba Yi Brain Hospital in Beijing. It will be the world’s first trial where the company’s neural stem cells will be injected directly into the brain to treat patients with chronic motor disorders from stroke.

For additional information, visit the company’s website at www.Neuralstem.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html